{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Relevant Biomarkers for the Treatment of Hematological Malignancies

Purpose of Activity

To provide information on treatments and relevant biomarkers for diffuse large B-cell lymphoma (DLBCL).

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Analyze the application of several different checkpoint inhibitors in the treatment of patients with various hematologic malignancies.
  2. Explain the latest findings about relevant genetic biomarkers for diffuse large B-cell lymphoma (DLBCL).
Price: $10.00

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0919
Published: September 2019
Expires: 6/3/2021
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Richard Simoneaux
Categories: Cancer , Hematology , Oncology
Topics: Biomarker